BNT162b2 vaccine effectiveness in chronic kidney disease patients—an observational study

BACKGROUND: Chronic kidney disease (CKD) is a risk factor for severe coronavirus disease 2019 (COVID-19). We aimed to evaluate the real-life effectiveness of the BNT162b2 messenger RNA vaccine for a range of outcomes in patients with CKD compared with matched controls. METHODS: Data from Israel'...

Descripción completa

Detalles Bibliográficos
Autores principales: Bielopolski, Dana, Libresco, Gilad, Barda, Noam, Dagan, Noa, Steinmetz, Tali, Yahav, Dafna, Charytan, David M, Balicer, Ran D, Rozen-Zvi, Benaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384353/
https://www.ncbi.nlm.nih.gov/pubmed/36147707
http://dx.doi.org/10.1093/ckj/sfac166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384353/
https://www.ncbi.nlm.nih.gov/pubmed/36147707
http://dx.doi.org/10.1093/ckj/sfac166

Ejemplares similares